TECHNOLOGY | HEALTH | CONSUMER | INDUSTRIAL | FINANCIAL | NATURAL | INVESTING
 

Latest Issues
Advanced Search
Subscribe
TWST Conferences
Subscribe Online
TWST Products
Technology
Healthcare
Consumer
Industry & Services
Financial Services
Natural Resources
Investing Strategies
Who is TWST?
Contact TWST
Contact TWST Europe
Sample Issue
Home

Click the button below to talk to a live representative from The Wall Street Transcript

 

The Wall Street Transcript publishes:

Internet Security & Identity Authentication Issue
Four analysts and top management from nine sector firms examine the Security/Internet Security & Identity Authentication sector in this 51 - page Issue from The Wall Street Transcript.
Investing Strategies Report
Weekly series of interviews with TWST Editors and top money managers

Let the best minds of Wall Street pick your stock
How has Special Stock Report been able to consistently outperform the major indices? Find out how!
 

 

Off The Record: Human Genome Science’s management is doing it quite right, a Biotech Expert reports Full article published: 10/03/2001     Money Managers, Analysts, Buysiders and Executives


For Subscribers
Get the complete article now!



HUMAN GENOME SCIENCES, INC. (Nasdaq:HGSI);

Four analysts, two experts and top management from thirty-seven sector firms examine the Biotechnology sector in this special 179-page issue from The Wall Street Transcript, available at (212/952-7433) or http://www.twst.com/info/info423.htm

“I feel that Human Genome Science’s management is doing it quite right,” offers a biotech expert. “There is really one big reason for that: HGSI is approaching mining the genome for drugs in an extraordinarily practical manner. Is it going to revolutionize the world? Probably — in 20 years. HGSI, unlike a company like Millenium, is only preparing to go forward in genomics. Bill Haseltine, CEO of HGSI, has some definite ideas on where he wants HGSI heading. Everything HGSI does is geared towards genomics. Not everybody else approaches genomics in that fashion. If you talk to HGSI’s IT guys, their clinical guys, their research guy or the bench people — they’re all focused on getting drugs out of the genome. HGSI is going to miss some really exciting stuff now, but that’s the breaks. HGSI can’t do everything. In 20 years they will be way ahead. In terms of mining the genome for drugs, HGSI is the best out there.

“I also want to mention that I feel Bill Haseltine is a great manager. I would let Bill Haseltine run any company that I owned. Regardless of ego, Haseltine has done a great job with HGSI and I have total faith in him.”

This special issue includes:

1) Biotechnology - In an in-depth (13,900 words) Analyst Roundtable, Peter Drake, Managing Director at Prudential Securities, Inc., Mary Ann Gray, Analyst focusing on both public and private healthcare investments at Federated Kaufman Fund, Michael King, Jr., Managing Director at Robertson Stephens and Elise Wang, Managing Director at Salomon Smith Barney, examine the outlook for the sector including new approaches to diseases, outlook for tools and technology companies and share specific stock recommendations.

2) Searching for Executive Leadership in Biotechnology - In an in-depth (2,600 words) Expert Interview, Robert Hennessy, Managing Director at The Hennessy Group, examines the outlook for the sector.

3) The Biotechnology Transformation - In an in-depth (2,500 words) Expert Interview, John Rhodes, Managing Partner for Pharmaceuticals and Life Sciences at Deloitte & Touche, examines the outlook for the sector.

4) The TWST confidential Off-The-Record survey of management performance at nineteen sector firms asked market insiders about the ability of management teams to create shareholder value.

5) CEO and Sponsored interviews (average 2,500 words). Top management of thirty-seven sector firms examine the outlook for their firm and the sector.


Tickers included in this excerpt: HGSI

For US quote, 
 enter ticker here:
For a European quote, 
 enter ticker here:
Have TWST notes emailed to you free:
Version: Email address:


For Subscribers
Get the complete article now!

Email this page

This interview is a small excerpt from a comprehensive management survey published in The Wall Street Transcript on 10/01/01. For more information call (212) 952 7400. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.

Copyright 2001, Wall Street Transcript Corp.

SECTOR LINKS

  • Drugs & Biotech
  • Healthcare Services

     

    • HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE